TREMFYRA

TREMFYRA® (guselkumab) has shown sustained clinical and endoscopic remission in ulcerative colitis patients over three years. This long-term data highlights the drug’s durability, a key factor in the competitive UC market. As a selective IL-23p19 inhibitor, TREMFYRA® targets inflammation precisely, potentially offering a favorable safety profile for chronic management. These findings strengthen its position as a valuable therapeutic option for moderate to severe UC.